Chris Schott
Stock Analyst at JP Morgan
(3.81)
# 678
Out of 5,241 analysts
161
Total ratings
58.04%
Success rate
6.04%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZTS Zoetis | Maintains: Overweight | $190 → $130 | $74.22 | +75.15% | 4 | May 8, 2026 | |
| VTRS Viatris | Maintains: Neutral | $17 → $18 | $16.48 | +9.22% | 3 | May 8, 2026 | |
| RPRX Royalty Pharma | Maintains: Overweight | $50 → $58 | $52.85 | +9.74% | 5 | May 7, 2026 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $28 → $30 | $19.86 | +51.06% | 6 | May 7, 2026 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Overweight | $35 → $40 | $34.29 | +16.65% | 21 | Apr 30, 2026 | |
| MRK Merck & Co. | Maintains: Overweight | $125 → $135 | $111.38 | +21.21% | 8 | Apr 6, 2026 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $225 → $250 | $226.71 | +10.27% | 1 | Mar 5, 2026 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,150 → $1,300 | $1,004.92 | +29.36% | 24 | Feb 5, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $850 → $950 | $698.25 | +36.05% | 9 | Feb 2, 2026 | |
| PRGO Perrigo Company | Maintains: Neutral | $20 → $18 | $10.61 | +69.65% | 14 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $14 → $12 | $13.40 | -10.45% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $675 → $775 | $528.79 | +46.56% | 9 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $260 | $210.39 | +23.58% | 4 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $145 → $150 | $129.58 | +15.76% | 8 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $11.93 | +17.35% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $185 → $175 | $192.95 | -9.30% | 4 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $326.31 | -17.26% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $25.33 | +34.23% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $1.57 | +600.64% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.42 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $57.00 | +36.84% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35,000 → $47,500 | $2.93 | +1,621,060.41% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.00 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $22.64 | +120.85% | 3 | Nov 2, 2018 |
Zoetis
May 8, 2026
Maintains: Overweight
Price Target: $190 → $130
Current: $74.22
Upside: +75.15%
Viatris
May 8, 2026
Maintains: Neutral
Price Target: $17 → $18
Current: $16.48
Upside: +9.22%
Royalty Pharma
May 7, 2026
Maintains: Overweight
Price Target: $50 → $58
Current: $52.85
Upside: +9.74%
Elanco Animal Health
May 7, 2026
Maintains: Overweight
Price Target: $28 → $30
Current: $19.86
Upside: +51.06%
Teva Pharmaceutical Industries
Apr 30, 2026
Maintains: Overweight
Price Target: $35 → $40
Current: $34.29
Upside: +16.65%
Merck & Co.
Apr 6, 2026
Maintains: Overweight
Price Target: $125 → $135
Current: $111.38
Upside: +21.21%
Johnson & Johnson
Mar 5, 2026
Maintains: Neutral
Price Target: $225 → $250
Current: $226.71
Upside: +10.27%
Eli Lilly and Company
Feb 5, 2026
Maintains: Overweight
Price Target: $1,150 → $1,300
Current: $1,004.92
Upside: +29.36%
Regeneron Pharmaceuticals
Feb 2, 2026
Maintains: Overweight
Price Target: $850 → $950
Current: $698.25
Upside: +36.05%
Perrigo Company
Dec 15, 2025
Maintains: Neutral
Price Target: $20 → $18
Current: $10.61
Upside: +69.65%
Nov 11, 2025
Maintains: Underweight
Price Target: $14 → $12
Current: $13.40
Upside: -10.45%
Nov 4, 2025
Maintains: Overweight
Price Target: $675 → $775
Current: $528.79
Upside: +46.56%
Nov 3, 2025
Maintains: Overweight
Price Target: $250 → $260
Current: $210.39
Upside: +23.58%
Oct 31, 2025
Maintains: Overweight
Price Target: $145 → $150
Current: $129.58
Upside: +15.76%
Sep 16, 2025
Maintains: Overweight
Price Target: $12 → $14
Current: $11.93
Upside: +17.35%
May 5, 2025
Maintains: Neutral
Price Target: $185 → $175
Current: $192.95
Upside: -9.30%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $326.31
Upside: -17.26%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $25.33
Upside: +34.23%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $1.57
Upside: +600.64%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $5.42
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $57.00
Upside: +36.84%
May 27, 2020
Maintains: Overweight
Price Target: $35,000 → $47,500
Current: $2.93
Upside: +1,621,060.41%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $2.00
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $22.64
Upside: +120.85%